



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

24th July, 2018

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sirs,

Subject: Media release: Q1

Please find enclosed a press release issued by the Company in respect of financial results for the first quarter ended 30th June, 2018.

This is for your information and record.

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

Encl:



PRESS RELEASE

Tuesday, 24th July 2018, Mumbai

GlaxoSmithKline Pharmaceuticals Limited delivers Q1 Revenues of 736 Crores, growing at 21%. Recommends a bonus issue of 1:1.

GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended 30th June 2018. Revenue from Operations for the quarter ended 30th June 2018 was at Rs. 736 crores, recording a growth of 21% as compared to the same prior year period.

Profit Before Tax (PBT) was at Rs. 138 crores and Profit After Tax (PAT) at Rs. 87 crores and EBITDA margin was 19% for the quarter.

The significant Revenue and Profit growth of this quarter is due to base effect of trade channel de-stocking ahead of the introduction of GST in the previous year. Furthermore, the Revenue of this quarter is not comparable to the prior year quarter due to the dynamics of GST rates on prices.

The Board of Directors at its Meeting held today have considered, approved and recommended a Bonus Issue of equity shares in the ratio of 1 (One) Equity Share of Rs. 10/- each for every 1 (One) Equity Share of Rs. 10/- each held by the shareholders of the Company as on the record date, subject to the approval of shareholders.

Commenting on the results, **A. Vaidheesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited** said,

“Our Company’s Revenue and Profit performance continue to maintain strong momentum with good performance from our key therapies in the quarter. Excluding the impacts of GST and our divested portfolio, we witnessed underlying double-digit, profitable growth with our priority portfolio, supported by robust volume growth.

In keeping with our goal to become one of the world’s most innovative, best performing and trusted healthcare companies, we are evolving our commercial operating model to invest resources on key products and patients/consumers to drive growth for our company. Identified therapies will also be supported by incremental field force during the course of the year.

Exceptional items for the current quarter includes a charge in establishment costs because of restructuring the commercial organisation to align with our new operating model and focused therapy investment.

We also launched, **Infanrix Hexa** (hexavalent DTaP - diphtheria, tetanus, acellular pertussis, Hepatitis B, Polio, Hib) in April. We are pleased to note the good response from paediatricians in the first quarter. I hope we will continue to generate confidence in the market around this brand and help protect more kids against 6 vaccine preventable diseases.

The Company is pleased to recommend a 1:1 bonus issue of shares as a distribution of reserves.”